Our group has previously shown that IFN-α treated CML patients who have successfully discontinued the treatment have increased amounts of NK-cells and CD8+ T-cells, and a distinct cytokine profile [20]. The gene discussed is CD8A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.